Peak takes no insurance at all, so theres no in-between
To investigate this issue Mojsov, Drucker and Habener joined forces with Jacques Philippe and William Chick, two other researchers at MGH

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Ozempic vs Insulin: Which Is More Effective for Weight Loss
(See here: Individual results may vary, and these medications should only be used under the guidance of a qualified healthcare professional
Read the Medication Guide provided by your pharmacist before your treatment starts